PE32196A1 - Granulo enterico de duloxetina - Google Patents

Granulo enterico de duloxetina

Info

Publication number
PE32196A1
PE32196A1 PE1995273613A PE27361395A PE32196A1 PE 32196 A1 PE32196 A1 PE 32196A1 PE 1995273613 A PE1995273613 A PE 1995273613A PE 27361395 A PE27361395 A PE 27361395A PE 32196 A1 PE32196 A1 PE 32196A1
Authority
PE
Peru
Prior art keywords
duloxetine
granules
pharmaceutically acceptable
partially neutralized
enteric
Prior art date
Application number
PE1995273613A
Other languages
English (en)
Inventor
Toshiro Fujii
Peter Lloyd Oren
Neil Robert Anderson
Toshihiro Ogura
Original Assignee
Shionogi And Company Ltd
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23055767&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE32196(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shionogi And Company Ltd, Lilly Co Eli filed Critical Shionogi And Company Ltd
Publication of PE32196A1 publication Critical patent/PE32196A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

CARACTERIZADO POR QUE COMPRENDE: a) UN NUCLEO QUE CONSTA DE DULOXETINA Y UN EXCIPIENTE ACEPTABLE FARMACEUTICAMENTE; SIENDO EL TAMANO MEDIO DE LA PARTICULA DE DULOXETINA ES 50 �M o MENOS; b) UNA CAPA DE SEPARACION OPCIONAL ACEPTABLE FARMACEUTICAMENTE TAL COMO SACAROSA; c) UNA CAPA ENTERICA COMPUESTA DE HIDROXIPROPILMETILCELULOSA ACETATO SUCCINATO (HPMCAS), LA QUE ES NEUTRALIZADA PARCIALMENTE CON IONES AMONIO HASTA EL GRADO EN QUE SE NEUTRALIZAN PARCIALMENTE GRUPOS DE ACIDO SUCCINICO, Y UN EXCIPIENTE ACEPTABLE FARMACEUTICAMENTE; Y d) UNA CAPA DE ACABADO OPCIONAL
PE1995273613A 1994-07-18 1995-07-12 Granulo enterico de duloxetina PE32196A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/276,232 US5508276A (en) 1994-07-18 1994-07-18 Duloxetine enteric pellets

Publications (1)

Publication Number Publication Date
PE32196A1 true PE32196A1 (es) 1996-08-07

Family

ID=23055767

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1995273613A PE32196A1 (es) 1994-07-18 1995-07-12 Granulo enterico de duloxetina

Country Status (30)

Country Link
US (1) US5508276A (es)
EP (1) EP0693282B1 (es)
JP (1) JP3707831B2 (es)
KR (1) KR100356240B1 (es)
CN (1) CN1106191C (es)
AT (1) ATE200620T1 (es)
AU (1) AU686384B2 (es)
BR (1) BR9503346A (es)
CA (1) CA2153856C (es)
CO (1) CO4410177A1 (es)
CZ (1) CZ288095B6 (es)
DE (1) DE69520711T2 (es)
DK (1) DK0693282T3 (es)
ES (1) ES2157297T3 (es)
GE (1) GEP20063944B (es)
GR (1) GR3036185T3 (es)
HU (1) HU221502B (es)
IL (1) IL114584A (es)
MY (1) MY116361A (es)
NO (2) NO312397B1 (es)
NZ (1) NZ272554A (es)
PE (1) PE32196A1 (es)
PL (1) PL181296B1 (es)
PT (1) PT693282E (es)
RU (1) RU2147231C1 (es)
SI (1) SI0693282T1 (es)
TW (1) TW382596B (es)
UA (1) UA41344C2 (es)
YU (1) YU49445B (es)
ZA (1) ZA955799B (es)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU709704B2 (en) * 1995-07-24 1999-09-02 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
ATE449603T1 (de) 1998-09-15 2009-12-15 Lilly Co Eli Verwendung von duloxetine zur behandlung von fibromyalgie
ATE400251T1 (de) * 1999-02-09 2008-07-15 Pfizer Prod Inc Zusammensetzungen basischer arzneistoffe mit verbesserter bioverfügbarkeit
IL130602A0 (en) * 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
DZ3282A1 (fr) * 2000-03-07 2001-09-13 Lilly Co Eli Traitement du psoriasis
JP2004525940A (ja) * 2001-03-29 2004-08-26 イーライ・リリー・アンド・カンパニー 火照りの処置のためのデュロキセチン
MXPA03011784A (es) 2001-06-22 2004-04-02 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
WO2003000292A1 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers
US20050272805A1 (en) * 2002-11-19 2005-12-08 Detke Michael J Treatment of gastrointestinal disorders with duloxetine
PL2446881T3 (pl) * 2003-07-24 2014-08-29 Glaxosmithkline Llc Folie rozpuszczające się w jamie ustnej
KR101252863B1 (ko) * 2004-04-08 2013-04-09 교와 핫꼬 기린 가부시키가이샤 안정성이 향상된 고형 제제 및 그 제조 방법
GB0410470D0 (en) * 2004-05-11 2004-06-16 Cipla Ltd Pharmaceutical compound and polymorphs thereof
TWI306858B (en) * 2004-12-23 2009-03-01 Teva Pharma Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
MX2007010931A (es) * 2005-03-08 2007-10-16 Teva Pharma Formas cristalinas de (s)-(+)-n,n-dimetil-3-(1-naftaleniloxi)-3-(2 -tienil)propanamina oxalato y la preparacion ellas.
EP1858874A1 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd. (s)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamine-di-p-toluoyl-l-tartarate and methods of preparation thereof
EP1904039A2 (en) * 2005-06-20 2008-04-02 Cadila Healthcare Ltd. Controlled release dosage formulation of duloxetine
US8153824B2 (en) * 2005-06-22 2012-04-10 The Wockhardt Company Antidepressant oral liquid compositions
PL1915137T3 (pl) 2005-08-10 2014-03-31 Add Advanced Drug Delivery Tech Ltd Preparat doustny o kontrolowanym uwalnianiu
US20060165776A1 (en) * 2005-08-31 2006-07-27 Ramesh Sesha Antidepressant oral pharmaceutical compositions
US7842717B2 (en) * 2005-09-22 2010-11-30 Teva Pharmaceutical Industries Ltd. DNT-maleate and methods of preparation thereof
US20080207923A1 (en) * 2005-09-22 2008-08-28 Santiago Ini Pure DNT-maleate and methods of preparation thereof
WO2007062119A1 (en) * 2005-11-23 2007-05-31 Auspex Pharmaceuticals, Inc. Substituted aryloxypropylamines with serotoninergic and/or norepinephrinergic activity
US7759500B2 (en) * 2005-12-05 2010-07-20 Teva Pharmaceutical Industries Ltd. 2-(N-methyl-propanamine)-3-(2-naphthol)thiophene, an impurity of duloxetine hydrochloride
DE102005060393A1 (de) * 2005-12-16 2007-06-21 Add Advanced Drug Delivery Technologies Ltd. Orales Präparat mit kontrollierter Freisetzung
MX2007011611A (es) * 2006-01-23 2007-10-18 Teva Pharma Fumarato de dnt y metodos de preparacion de ellos.
EP1820800A1 (en) * 2006-02-17 2007-08-22 KRKA, tovarna zdravil, d.d., Novo mesto Crystalline forms of duloxetine hydrochloride and processes for their preparation
KR200416582Y1 (ko) 2006-03-07 2006-05-19 김정배 건강신발
BRPI0711606A2 (pt) * 2006-05-22 2012-02-14 Teva Pharma formulações de hidrocloreto de duloxetina de liberação retardada
WO2007139984A2 (en) * 2006-05-23 2007-12-06 Teva Pharmaceutical Industries Ltd. Duloxetine hcl polymorphs
JP5052051B2 (ja) * 2006-06-16 2012-10-17 トーアエイヨー株式会社 腸溶性顆粒剤及びその製造方法
WO2008020286A2 (en) * 2006-08-14 2008-02-21 Torrent Pharmaceuticals Limited Pharmaceutical compositions of duloxetine
CN101190208B (zh) * 2006-11-30 2011-11-02 石药集团中奇制药技术(石家庄)有限公司 一种含有盐酸度洛西汀的药物制剂及其制备方法
WO2008077645A1 (en) 2006-12-22 2008-07-03 Synthon B.V. Process for making duloxetine and related compounds
EP1938840A1 (en) * 2006-12-27 2008-07-02 LEK Pharmaceuticals D.D. Duloxetine composition
BRPI0720958A2 (pt) * 2006-12-27 2014-03-18 Lek Pharmaceuticals Omposição de duloxetina
EP2018860A1 (en) * 2007-07-16 2009-01-28 LEK Pharmaceuticals D.D. Duloxetine composition
US20080226711A1 (en) * 2007-03-12 2008-09-18 Torrent Pharmaceuticals Ltd. Pharmaceutical compositions of duloxetine
WO2008129501A2 (en) * 2007-04-20 2008-10-30 Wockhardt Research Centre Pharmaceutical compositions of duloxetine
US20100172972A1 (en) * 2007-05-21 2010-07-08 Sun Pharmaceutical Industries Limited Enteric coated pharmaceutical compositions
GB0712220D0 (en) * 2007-06-23 2007-08-01 Arrow Int Ltd Duloxetine formulation
WO2009066181A2 (en) * 2007-07-09 2009-05-28 Combino Pharm, S.L. Oral delayed-release duloxentine hydrochloride pellets
CL2008002032A1 (es) * 2007-07-13 2009-01-23 Synthon Bv Forma de dosis farmaceutica que posee una pluralidad de pellets, cada pellet comprende, un nucleo de pellet con un diametro de 600 a 1000 micrometros, capa de farmaco que comprende duloxetina o una sal y aglutinante de preferencia metil celulosa, una capa de separacion y una capa de recubrimiento enterico; proceso de preparacion
WO2009087657A2 (en) * 2007-11-03 2009-07-16 Alkem Laboratories Ltd. Stable pharmaceutical composition of duloxetine and process for its preparation
EP2231169B1 (en) * 2007-12-06 2016-05-04 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
EP2240162A4 (en) 2007-12-06 2013-10-09 Bend Res Inc NANOTE PARTICLES WITH A NON-IONIZABLE POLYMER AND AN AMIN-FUNCTIONALIZED METHACRYLATE COPOLYMER
JP2011510024A (ja) * 2008-01-25 2011-03-31 アルファファーム ピーティーワイ リミテッド デュロキセチンの遅延放出医薬組成物
US20090226517A1 (en) * 2008-02-06 2009-09-10 Vinita Umashankar Vyas Pharmaceutical formulations comprising duloxetine
WO2009118756A2 (en) * 2008-03-24 2009-10-01 Lupin Limited Delayed release compositions of duloxetine
US20110038933A1 (en) * 2008-05-06 2011-02-17 Dexcell Ltd. Stable benzimidazole formulation
EP2133072A1 (en) 2008-06-13 2009-12-16 KRKA, D.D., Novo Mesto Gastro-resistant pharmaceutical oral compositions comprising duloxetine or its pharmaceutically acceptable derivatives
US20100040680A1 (en) * 2008-08-15 2010-02-18 Felix Lai Multiparticulate selective serotonin and norepinephrine reuptake inhibitor formulation
WO2010037849A1 (en) * 2008-10-02 2010-04-08 Laboratorios Del Dr. Esteve, S.A. Duloxetine enteric pellets
CN101756960B (zh) * 2008-12-26 2012-06-27 上海中西制药有限公司 一种度洛西汀肠溶制剂及其芯材和制备方法
WO2010078878A1 (en) * 2009-01-12 2010-07-15 Synthon B.V. Duloxetine formulations
WO2010150219A1 (en) 2009-06-25 2010-12-29 Wockhardt Research Centre Pharmaceutical composition of duloxetine or pharmaceutically acceptable salts thereof
DE102009033621A1 (de) 2009-07-17 2011-01-20 Add Technologies Ltd. Trennschichten für pharmazeutische Zubereitungen zur Verhinderung von Wechselwirkungen zwischen Arzneistoffen und pharmazeutisch-technologischen Hilfsstoffen
EP2477614A2 (en) * 2009-09-17 2012-07-25 Cadila Healthcare Limited Pharmaceutical compositions for reducing alcohol-induced dose dumping
US10071059B2 (en) * 2009-12-18 2018-09-11 Frieslandcampina Nederland Holding B.V. Co-processed tablet excipient composition its preparation and use
HUE042593T2 (hu) * 2010-03-09 2019-07-29 Alkermes Pharma Ireland Ltd Alkoholnak ellenálló enterális gyógyszerkészítmények
EP2377525A1 (en) * 2010-03-26 2011-10-19 Laboratorios del Dr. Esteve S.A. Duloxetine enteric pellets
KR20130071430A (ko) * 2010-05-25 2013-06-28 헤테로 리서치 파운데이션 둘록세틴의 경구 약제학적 조성물
CN102908331A (zh) * 2011-08-01 2013-02-06 浙江九洲药物科技有限公司 一种盐酸度洛西汀肠溶胶囊及其制备方法
ES2655622T3 (es) 2012-04-30 2018-02-20 Tillotts Pharma Ag Una formulación de fármaco de liberación retardada
JP6626712B2 (ja) 2012-05-02 2019-12-25 キャプシュゲル・ベルジウム・エヌ・ヴィ 放出制御ポリマーの水性分散液並びにそのシェル及びカプセル
CN103505421B (zh) * 2012-06-29 2018-04-27 石药集团中奇制药技术(石家庄)有限公司 一种盐酸度洛西汀的肠溶微丸制剂
CN103211777A (zh) * 2013-03-31 2013-07-24 北京万全阳光医学技术有限公司 一种盐酸度洛西汀的药物制剂及其制备的方法
GR1008228B (el) * 2013-04-23 2014-06-16 "Φαρματεν Α.Β.Ε.Ε.", Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου
EP2813218B1 (en) 2013-06-14 2022-08-24 Shin-Etsu Chemical Co., Ltd. Method for producing aqueous enteric coating liquid, solid preparation, and method for producing same
CN103393615B (zh) * 2013-07-24 2015-07-15 海南华益泰康药业有限公司 一种度洛西汀肠溶小丸及其制备方法
PL224543B1 (pl) 2013-08-21 2017-01-31 Pabianickie Zakłady Farm Polfa Spółka Akcyjna Dojelitowa tabletka duloksetyny
AU2013404367B2 (en) 2013-10-29 2020-02-27 Tillotts Pharma Ag A delayed release drug formulation
EP3065720A1 (en) 2013-11-04 2016-09-14 Capsugel Belgium NV Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole
KR102377103B1 (ko) * 2014-05-20 2022-03-23 뉴트리션 & 바이오사이언시즈 유에스에이 1, 엘엘씨 에스테르화된 셀룰로오스 에테르를 포함하는 캡슐 쉘
CN107072980A (zh) * 2014-08-22 2017-08-18 麦迪帕斯有限公司 在药物递送中使用的用于大麻素包衣的组合物和方法
US10471152B2 (en) * 2014-08-29 2019-11-12 Capsugel Belgium Nv Colloidal dispersion comprising HPMCAS
US20170182070A1 (en) 2014-10-08 2017-06-29 Mayne Pharma International Pty Ltd. Controlled Release Doxycycline
US9668975B2 (en) 2014-10-14 2017-06-06 PharmaDax Inc. Method of preparing drug agglomerate
CN105726488B (zh) * 2014-12-08 2020-10-20 上海爱科百发生物医药技术有限公司 含有呼吸道合胞病毒抑制剂的肠溶微丸及其制备方法
KR101625344B1 (ko) 2015-12-21 2016-06-08 주식회사 유영제약 세레콕시브 및 둘록세틴을 함유하는 약제학적 조성물
CN105534949A (zh) * 2016-01-06 2016-05-04 北京修正创新药物研究院有限公司 一种盐酸度洛西汀的肠溶微丸制剂
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
JP6815109B2 (ja) * 2016-06-23 2021-01-20 キョーリンリメディオ株式会社 デュロキセチンまたは薬学的に許容されるその塩を有効成分とする医薬組成物
JP6856326B2 (ja) * 2016-07-15 2021-04-07 富士化学工業株式会社 腸放出粒子組成物
CN106166144A (zh) * 2016-08-12 2016-11-30 海南合瑞制药股份有限公司 一种盐酸度洛西汀肠溶胶囊药物组合物
JP2018172361A (ja) * 2016-10-14 2018-11-08 大原薬品工業株式会社 光安定性を改善した、デュロキセチンを含有する固形製剤
US9839626B1 (en) * 2016-12-14 2017-12-12 Sun Pharmaceutical Industries Limited Duloxetine sprinkles
JP7072431B2 (ja) * 2017-04-14 2022-05-20 富士化学工業株式会社 錠剤及びその製造方法
JP6972674B2 (ja) * 2017-06-06 2021-11-24 ニプロ株式会社 経口医薬製剤
JP2020029447A (ja) * 2018-06-25 2020-02-27 大原薬品工業株式会社 腸溶性高分子及び抗付着剤を含有する顆粒
CN115844846B (zh) * 2018-10-25 2025-08-05 上海上药中西制药有限公司 盐酸度洛西汀肠溶制剂、其主药层及其混悬液、其隔离层及其包衣液、及其制备方法
JP7050714B2 (ja) * 2019-04-04 2022-04-08 信越化学工業株式会社 腸溶性コーティング用組成物及び固形製剤の製造方法
JP2020189815A (ja) * 2019-05-23 2020-11-26 東和薬品株式会社 デュロキセチン製剤およびその安定化方法
EP4025206A1 (en) 2019-09-02 2022-07-13 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and compositions for treating pax6- deficiency related disease
WO2021126098A1 (en) * 2019-12-18 2021-06-24 Santa Farma İlaç Sanayi̇ A.Ş. Gastro-resistant pellet comprising duloxetine
WO2021126099A1 (en) * 2019-12-18 2021-06-24 Santa Farma İlaç Sanayi̇ A.Ş. An enteric coated pellet comprising duloxetine hydrochloride with optimized degrees of neutralization
WO2022115054A1 (en) * 2020-11-27 2022-06-02 Santa Farma Ilac Sanayii A.S. Enteric coated duloxetine compositions
CN116251078B (zh) * 2021-12-09 2025-12-19 河北以岭医药研究院有限公司 一种盐酸度洛西汀肠溶胶囊及其制备方法
WO2024117996A1 (en) * 2022-11-30 2024-06-06 Santa Farma Ilac Sanayii A.S. Bioequivalent oral pharmaceutical composition comprising duloxetine hydrochloride
TW202535386A (zh) 2023-10-16 2025-09-16 法商拜爾普羅傑特醫藥有限公司 腸溶包衣必托里賽(pitolisant)調配物及使用方法
EP4681704A1 (en) 2024-07-18 2026-01-21 BIOPROJET Pharma New formulations of pitolisant

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS517116A (en) * 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
CH649216A5 (de) * 1979-08-16 1985-05-15 Sandoz Ag Verfahren zur auftragung eines magensaftresistenten filmes auf einen heilmittelkern und feste einheitsdosierungsform mit magensaftresistentem film.
US5019302A (en) 1986-03-12 1991-05-28 Washington University Technology Associates, Inc. Method for granulation
US5100592A (en) 1986-03-12 1992-03-31 Washington University Technology Associated, Inc. Method and apparatus for granulation and granulated product
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
JP2773959B2 (ja) * 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
JPH04346930A (ja) * 1991-05-25 1992-12-02 Sumitomo Pharmaceut Co Ltd 安定なアスピリン腸溶錠
RU2024520C1 (ru) * 1991-10-08 1994-12-15 Институт органической химии Уральского отделения РАН 10-метокси-5- метил-6- (1',1'- диоксидо-2'- метахлорфенилазо -3'- гидрокси -4'-метоксибензо(в)тиофен- 7-ил) -5h-3,4,6,7- тетрагидрофуро [4.3.2-q] [3]бензазоцин, обладающий антидепрессивным действием
RU2024526C1 (ru) * 1991-10-08 1994-12-15 Институт органической химии Уральского отделения РАН 5h- 3,4,6,7- тетрагидро-10- метокси-5-метил-6- (1',1'- диоксидо-3'- мета- хлоранилино-4'- метокси- бензо [в] тиофен -7'-ил) -фуро[4,3,2-q] [3]бензазоцин, обладающий антидепрессивным действием
ZA93694B (en) * 1993-02-01 1993-06-03 Lilly Co Eli Pharmaceutical treatments.
US5362886A (en) * 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis

Also Published As

Publication number Publication date
EP0693282B1 (en) 2001-04-18
KR960003722A (ko) 1996-02-23
RU2147231C1 (ru) 2000-04-10
MY116361A (en) 2004-01-31
ATE200620T1 (de) 2001-05-15
JPH0840895A (ja) 1996-02-13
EP0693282A3 (en) 1996-12-18
TW382596B (en) 2000-02-21
CN1128141A (zh) 1996-08-07
HUT72466A (en) 1996-04-29
GEP20063944B (en) 2006-10-10
EP0693282A2 (en) 1996-01-24
CA2153856C (en) 2005-05-10
PT693282E (pt) 2001-07-31
KR100356240B1 (ko) 2002-12-26
ZA955799B (en) 1997-01-13
ES2157297T3 (es) 2001-08-16
CN1106191C (zh) 2003-04-23
YU48095A (sh) 1998-07-10
PL309588A1 (en) 1996-01-22
CO4410177A1 (es) 1997-01-09
NO2005002I2 (no) 2009-10-05
NO2005002I1 (no) 2005-02-28
YU49445B (sh) 2006-03-03
NZ272554A (en) 1996-11-26
AU686384B2 (en) 1998-02-05
DE69520711T2 (de) 2001-09-20
GR3036185T3 (en) 2001-10-31
UA41344C2 (uk) 2001-09-17
CZ288095B6 (cs) 2001-04-11
NO312397B1 (no) 2002-05-06
US5508276A (en) 1996-04-16
IL114584A (en) 1999-09-22
NO952786D0 (no) 1995-07-13
NO952786L (no) 1996-01-19
HU221502B (en) 2002-10-28
IL114584A0 (en) 1995-11-27
SI0693282T1 (en) 2002-02-28
CZ180595A3 (en) 1996-03-13
JP3707831B2 (ja) 2005-10-19
HU9502134D0 (en) 1995-09-28
PL181296B1 (pl) 2001-07-31
CA2153856A1 (en) 1996-01-19
AU2505195A (en) 1996-02-01
DE69520711D1 (de) 2001-05-23
DK0693282T3 (da) 2001-05-07
BR9503346A (pt) 1996-02-27

Similar Documents

Publication Publication Date Title
CO4410177A1 (es) Granulos entericos de duloxetina
LU88334I2 (fr) 9-(1,3-Dihydroxy-2-propoxyméthyl) guanine et ses sels pharmaceutiquement acceptables.
NO174547C (no) Analogifremgangsmåte ved fremstilling av terapeutisk aktive didehydro-vitamin-D3-derivater
NO834052L (no) Enterisk belegg for farmasoeytiske doseringsformer
UA66800C2 (uk) Фармацевтична форма препарату для перорального прийому, що містить сполуку з противиразковою активністю, і спосіб її одержання
FI981017A0 (fi) Proteiinien uutto hiilidioksidiin
DE68911457D1 (de) Plasmaspritzbrennerverlängerung zum Anbringen von Schichten in Nuten.
IL126938A0 (en) Process for production of five-membered or six-membered cyclic ethers in particular of anhydropolyols
FI934971A0 (fi) Anlaeggning foer foerbraenning av spraengaemnen
FR2626469B1 (fr) Nouvelles preparations cosmetiques contenant un extrait des parties aeriennes de cichorium intybus l
NO882582D0 (no) Tredimensjonal, iterativ, strukturell modellering av seismiske data.
DE69033970D1 (de) Huperzin a analoge verbindungen
DE69206034D1 (de) Korrosionsschutz von FeMn mittels Ionenimplantierung.
WO2002062946A3 (en) Identification of novel ms4a gene family members expressed by hematopoietic cells
FI945322L (fi) Menetelmä 2',3'-didehydro-2',3'-dideoksinukleosidien laajamittaista valmistusta varten
FI950883A0 (fi) BAPP-C100-reseptorin kloonaus ja ilmentäminen
FR2672888B1 (fr) Nouvelles urees et thiourees, leur preparation et leur application en therapeutique.
IT1151793B (it) Procedimento per la preparazione di antigene superficiale puro dell'epatite b da plasma umano
IT1241660B (it) Copolimero vinil acetato/vinil alcool,processo di produzione dello stesso e suo impiego
Shaw et al. Cretaceous palynomorphs of Taiwan (2)-taxonomic treatment
JPS5224232A (en) Method for antistatic coating of signs of power transmission pylon
JPS5248280A (en) Dust cleaner of inner surfce of cylindrical body
Marcozzi L'evoluzione della psiche
IT1193493B (it) Metodo per l'applicazione di un agente durevole,antistatico,per la liberazione dello sporco
ID26442A (id) Metoda analisa bujur sangkar gaya (b.s.g) untuk menghasilkan daya dukung pondasi kelompok tiang pancang berkapasitas tinggi

Legal Events

Date Code Title Description
FG Grant, registration
MK Expiration of term